JP2018517150A - Fviiiインヒビター検出のための新規な自動化スクリーニング法の開発 - Google Patents
Fviiiインヒビター検出のための新規な自動化スクリーニング法の開発 Download PDFInfo
- Publication number
- JP2018517150A JP2018517150A JP2018510328A JP2018510328A JP2018517150A JP 2018517150 A JP2018517150 A JP 2018517150A JP 2018510328 A JP2018510328 A JP 2018510328A JP 2018510328 A JP2018510328 A JP 2018510328A JP 2018517150 A JP2018517150 A JP 2018517150A
- Authority
- JP
- Japan
- Prior art keywords
- patient
- inhibitor
- sample
- ratio
- factor viii
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/745—Assays involving non-enzymic blood coagulation factors
- G01N2333/755—Factors VIII, e.g. factor VIII C [AHF], factor VIII Ag [VWF]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Diabetes (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
本出願は、米国特許仮出願第62/157,709号(2015年5月6日出願)の利益を主張する。
Claims (20)
- 患者試料中の第VIII因子インヒビターの存在を判定する方法であって、前記方法は、
患者試料と関連付けられ、患者の傾き(Ps)を有する患者曲線を作成することと;
対照試料と関連付けられ、対照の傾き(Cs)を有する標準曲線を作成し、
前記PsおよびCs曲線が、前記FVIII凝固活性に対して前記患者試料および前記対照試料の一連の希釈物における複数の凝固時間ポイントをプロットすることによって作成されることと;
前記PsおよびCsを比較してPs/Cs平行度比を得ることであって、ここで約0.45未満のPs/Cs平行度比が、前記患者試料中の第VIII因子インヒビターの存在の指標であることと、を含む方法。 - 前記Ps/Cs平行度比が、凝固検出機と電子的に接続したマイクロプロセッサによって判定される、請求項1に記載の方法。
- 0.45未満の前記比を決定すること、および前記第VIII因子インヒビターの前記存在を伴う病態の治療のために少なくとも1つの薬剤を前記患者に対して投与することをさらに含む、請求項1に記載の方法。
- 前記病態が血友病Aである、請求項3に記載の方法。
- 前記病態が自己免疫疾患である、請求項3に記載の方法。
- 前記薬剤が下記:ヒト第VIII因子、ブタ第VIII因子、およびFVIIIバイパス剤のうちの1つ以上である、請求項3に記載の方法。
- 前記マイクロプロセッサによる出力を作成することであって、前記出力は人間のユーザにより目視でもしくは聞こえるように認識することができるか、またはコンピュータにより読み取り可能なデジタル情報などであり、ここで、前記出力は前記Ps/Cs比の指標を含む出力であることをさらに含む、請求項2に記載の方法。
- 患者試料中の凝固インヒビターの存在を判定する方法であって、前記方法は、
凝固インヒビターが患者試料中に存在するかどうかを、
前記患者試料と関連付けられ、患者の傾き(Ps)を有する患者曲線を作成することと;
対照試料と関連付けられ、対照の傾き(Cs)を有する標準曲線を作成し、
前記PsおよびCs曲線が、前記凝固活性に対して前記患者試料および前記対照試料の一連の希釈物における複数の凝固時間ポイントをプロットすることによって作成されることと;
前記Psおよび前記Csを比較してPs/Cs平行度比を得ることであって、ここで所定比未満のPs/Cs平行度比が、前記患者試料中の凝固インヒビターの存在指標であることと、によって検出することを含む方法。 - 前記所定比が約0.45である、請求項8に記載の方法。
- 前記凝固インヒビターがダビガトランである、請求項8に記載の方法。
- 前記凝固インヒビターが第VIII因子インヒビターである、請求項8に記載の方法。
- 前記凝固剤が哺乳動物の第VIII因子である、請求項8に記載の方法。
- 患者試料中の抗凝固化合物の存在を判定、およびこのような患者を治療する方法であって、前記方法は、
前記体液の患者試料を得ることと;
抗凝固化合物が前記患者試料中に存在するかどうかを、
前記患者試料と関連付けられ、患者の傾き(Ps)を有する患者曲線を作成することと;
対照試料と関連付けられ、対照の傾き(Cs)を有する標準曲線を作成し、前記PsおよびCs曲線が、前記凝固活性に対して前記患者試料および前記対照試料の一連の希釈物における複数の凝固時間ポイントをプロットすることによって作成されることと;
前記Psおよび前記Csを比較してPs/Cs平行度比を得ることと;により検出することと:
所定比未満のPs/Cs平行度比に対応して、前記患者に有効量の凝固剤を投与することと、を含む方法。 - 前記所定比が約0.45である、請求項13に記載の方法。
- 前記抗凝固化合物が第VIII因子インヒビターである、請求項13に記載の方法。
- 前記凝固剤が哺乳動物の第VIII因子である、請求項15に記載の方法。
- 前記抗凝固化合物がダビガトランである、請求項13に記載の方法。
- 前記凝固剤がイダルシズマブである、請求項17に記載の方法。
- 前記抗凝固化合物がリバーロキサバンである、請求項13に記載の方法。
- 前記凝固剤が非活性化プロトロンビン複合濃縮物である、請求項19に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562157709P | 2015-05-06 | 2015-05-06 | |
US62/157,709 | 2015-05-06 | ||
PCT/US2016/031324 WO2016179547A1 (en) | 2015-05-06 | 2016-05-06 | Development of novel automated screening method for detection of fviii inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2018517150A true JP2018517150A (ja) | 2018-06-28 |
JP6625730B2 JP6625730B2 (ja) | 2019-12-25 |
Family
ID=57217837
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018510328A Expired - Fee Related JP6625730B2 (ja) | 2015-05-06 | 2016-05-06 | Fviiiインヒビター検出のための新規な自動化スクリーニング法の開発 |
Country Status (5)
Country | Link |
---|---|
US (2) | US20180292420A1 (ja) |
EP (1) | EP3292407A4 (ja) |
JP (1) | JP6625730B2 (ja) |
CN (1) | CN108139383A (ja) |
WO (1) | WO2016179547A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020218425A1 (ja) | 2019-04-26 | 2020-10-29 | 積水メディカル株式会社 | 凝固因子インヒビター力価の測定方法 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110782989B (zh) * | 2019-09-18 | 2022-06-17 | 平安科技(深圳)有限公司 | 数据分析方法、装置、设备及计算机可读存储介质 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH10508945A (ja) * | 1994-11-13 | 1998-09-02 | ザ スクリップス リサーチ インスティテュート | 血栓性疾患の診断方法 |
WO2009153964A1 (ja) * | 2008-06-18 | 2009-12-23 | 積水メディカル株式会社 | 血液凝固時間の延長原因の判定法 |
WO2015013495A1 (en) * | 2013-07-26 | 2015-01-29 | The University Of North Carolina At Chapel Hill | Methods and compositions for detecting coagulation inhibitors |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5576291A (en) * | 1993-09-13 | 1996-11-19 | Baxter International Inc. | Activated factor VIII as a therapeutic agent and method of treating factor VIII deficiency |
NZ592837A (en) * | 2008-11-14 | 2012-10-26 | Portola Pharm Inc | Antidotes for factor xa inhibitors and methods of using the same in combination with blood coagulating agents |
-
2016
- 2016-05-06 JP JP2018510328A patent/JP6625730B2/ja not_active Expired - Fee Related
- 2016-05-06 WO PCT/US2016/031324 patent/WO2016179547A1/en active Application Filing
- 2016-05-06 EP EP16790197.4A patent/EP3292407A4/en not_active Ceased
- 2016-05-06 CN CN201680026294.2A patent/CN108139383A/zh active Pending
- 2016-05-06 US US15/572,085 patent/US20180292420A1/en not_active Abandoned
-
2021
- 2021-01-19 US US17/151,936 patent/US20210140985A1/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH10508945A (ja) * | 1994-11-13 | 1998-09-02 | ザ スクリップス リサーチ インスティテュート | 血栓性疾患の診断方法 |
WO2009153964A1 (ja) * | 2008-06-18 | 2009-12-23 | 積水メディカル株式会社 | 血液凝固時間の延長原因の判定法 |
WO2015013495A1 (en) * | 2013-07-26 | 2015-01-29 | The University Of North Carolina At Chapel Hill | Methods and compositions for detecting coagulation inhibitors |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020218425A1 (ja) | 2019-04-26 | 2020-10-29 | 積水メディカル株式会社 | 凝固因子インヒビター力価の測定方法 |
Also Published As
Publication number | Publication date |
---|---|
US20180292420A1 (en) | 2018-10-11 |
CN108139383A (zh) | 2018-06-08 |
EP3292407A1 (en) | 2018-03-14 |
WO2016179547A1 (en) | 2016-11-10 |
EP3292407A4 (en) | 2019-01-02 |
JP6625730B2 (ja) | 2019-12-25 |
US20210140985A1 (en) | 2021-05-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Bliden et al. | Determination of non-Vitamin K oral anticoagulant (NOAC) effects using a new-generation thrombelastography TEG 6s system | |
Bowyer et al. | Specific and global coagulation assays in the diagnosis of discrepant mild hemophilia A | |
Quiroga et al. | Is my patient a bleeder? A diagnostic framework for mild bleeding disorders | |
Bonar et al. | Overview of hemostasis and thrombosis and contribution of laboratory testing to diagnosis and management of hemostasis and thrombosis disorders | |
Favaloro | Laboratory identification of von Willebrand disease: technical and scientific perspectives | |
Douxfils et al. | Assessment of the analytical performances and sample stability on ST Genesia system using the STG‐DrugScreen application | |
Klose et al. | Evaluation of coagulation status in dogs with naturally occurring canine hyperadrenocorticism | |
Stokol et al. | Evaluation of latex agglutination kits for detection of fibrin (ogen) degradation products and D‐dimer in healthy horses and horses with severe colic | |
Lima‐Oliveira et al. | Sodium citrate blood contamination by K2‐ethylenediaminetetraacetic acid (EDTA): impact on routine coagulation testing | |
US20210140985A1 (en) | Development of novel automated screening method for detection of fviii inhibitors | |
Rodgers et al. | Chromogenic factor VIII assays for improved diagnosis of hemophilia A | |
Hayward | Diagnosis and management of mild bleeding disorders | |
Suehiro et al. | Probability of soluble tissue factor release lead to the elevation of D-dimer as a biomarker for traumatic brain injury | |
Milos et al. | Overall hemostasis potential and aPTT‐clot waveform analysis as powerful laboratory diagnostic tools for identification of hemophilia A patients with unexpected bleeding phenotype | |
Favaloro et al. | Hemostasis and thrombosis: an overview focusing on associated laboratory testing to diagnose and help manage related disorders | |
Shaw et al. | Coagulation assays and direct oral anticoagulant levels among patients having an elective surgery or procedure | |
AU2017257267B2 (en) | Method and kit for identifying lupus anticoagulant (LA) associated with antiphospholipid syndrome | |
Morales et al. | Effects of 2 concentrations of sodium citrate on coagulation test results, von Willebrand factor concentration, and platelet function in dogs | |
Stevens et al. | Thrombophilic evaluation in patients with acute pulmonary embolism | |
Milos et al. | New quantitative aPTT waveform analysis and its application in laboratory management of haemophilia A patients | |
Ma et al. | Evaluation of the bleeding patient | |
Schütte et al. | The one‐stage assay or chromogenic assay to monitor baseline factor VIII levels and desmopressin effect in non‐severe haemophilia A: Superiority or non‐inferiority? | |
Ruinemans-Koerts et al. | Non-parallelism in the one-stage coagulation factor assay is a phenomenon of lupus anticoagulants and not of individual factor inhibitors | |
Forster et al. | Detection of acute traumatic coagulopathy by viscoelastic haemostatic assays compared to standard laboratory tests: a systematic review | |
Favaloro et al. | Check for updates Chapter |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180109 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180316 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20180706 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20180706 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20181003 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20181204 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20190227 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20190426 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190523 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20191029 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20191127 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6625730 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |